Fundamental leadership · SEC EDGAR · no analyst estimates · as of 2026-09-10
Which industries lead on earnings and sales, today. As of 2026-09-10, 4,465 companies clear the eligibility gates and 1,340 rank Leader or Strong on filed EPS and revenue growth. The strongest industry group is Precious Metals with 29 Leader or Strong names. 19.9% of eligible companies also sit in the top relative-strength quintile — fundamentals and price agreeing.
Industry / Healthcare
| Ticker | Company | Rank | Δ3wk | Verdict | EPS YoY | Sales YoY | Margin Δ | 6M RS | Filed |
|---|---|---|---|---|---|---|---|---|---|
| HCWB | HCW Biologics Inc. Common Stock | 99 | ±0 | Leader | loss widened 71% | >+999% | — | 23 | 2026-08-14 |
| LQDA | Liquidia Corporation Common StockHuman Therapeutics | 99 | ±0 | Leader | to profit↑ | >+999% | >+10,000 bps | 94 | 2026-08-12 |
| ORMP | Oramed Pharmaceuticals Inc. | 99 | ±0 | Leader | +494% | — | — | 87 | 2026-08-10 |
| QTTB | Q32 Bio Inc. Common Stock | 99 | ±0 | Leader | loss narrowed 44% | — | — | 92 | 2026-08-05 |
| SLGL | Sol-Gel Technologies Ltd. Ordinary Shares | 99 | ±0 | Leader | >+999% | +218% | — | 19 | 2026-03-19 |
| ABUS | Arbutus Biopharma Corporation Common Stock | 98 | ±0 | Leader | to loss | -91% | >+10,000 bps | 61 | 2026-08-12 |
| CGEN | Compugen Ltd | 98 | ±0 | Leader | to profit | +161% | +9649 bps | 61 | 2026-03-02 |
| LKFT | Lakefront Biotherapeutics American Depositary Shares | 98 | ±0 | Leader | +335% | +304% | +9485 bps | — | 2026-03-26 |
| MGTX | MeiraGTx Holdings plc Ordinary Shares | 98 | ±0 | Leader | to profit | >+999% | >+10,000 bps | 93 | 2026-08-13 |
| PTGX | Protagonist Therapeutics, Inc | 98 | ±0 | Leader33 | to profit↑ | >+999%↑ | +923 bps | 91 | 2026-08-05 |
| ZVRA | Zevra Therapeutics, Inc. Common Stock | 98 | ±0 | Leader | -88% | +53%↓ | >+10,000 bps | 70 | 2026-08-05 |
| ATNM | Actinium Pharmaceuticals, Inc | 97 | ±0 | Leader | to profit↑ | — | — | 64 | 2026-08-07 |
| BCRX | BioCryst Pharmaceuticals Inc | 97 | ±0 | Leader | >+999% | +34% | -4301 bps | 46 | 2026-08-05 |
| ETON | Eton Pharmaceutcials, Inc. Common Stock | 97 | ±0 | Leader | to profit | +99% | +1683 bps | 99 | 2026-08-13 |
| IRWD | Ironwood Pharmaceuticals, Inc. - Class A | 97 | ±0 | Leader | +121% | +33% | +3638 bps | 61 | 2026-08-06 |
| NBIX | Neurocrine Biosciences IncHuman Therapeutics | 97 | ±0 | Leader | +31% | +39% | +384 bps | 75 | 2026-07-31 |
| PLX | Protalix BioTherapeutics, Inc. Common Stock | 97 | -1 | Leader | to profit | +27% | +1561 bps | 42 | 2026-08-12 |
| RADX | Radiopharm Theranostics Limited American Depositary Shares | 97 | ±0 | Leader | loss narrowed 86% | >+999% | — | 8 | 2025-09-18 |
| TGTX | TG Therapeutics, Inc.Human Therapeutics | 97 | ±0 | Leader | -71% | +70% | -186 bps | 96 | 2026-08-05 |
| ANAB | AnaptysBio, Inc. Common Stock | 96 | -1 | Leader | loss widened 44% | -8%↓ | >+10,000 bps | 31 | 2026-05-12 |
| ARQT | Arcutis Biotherapeutics, Inc. Common StockHuman Therapeutics | 96 | ±0 | Leader | to profit | +59%↓ | +4050 bps | 46 | 2026-08-05 |
| ARVN | Arvinas, Inc | 96 | ±0 | Leader | to profit | >+999% | +2607 bps | 15 | 2026-08-04 |
| FENC | Fennec Pharmaceuticals Inc. Common Stock | 96 | ±0 | Leader | to profit↑ | +85% | +2716 bps | 88 | 2026-08-13 |
| ARGX | argenx SE American Depositary SharesHuman Therapeutics | 95 | ±0 | Leader | +53% | +89% | +2577 bps | 85 | 2026-03-19 |
| CRMD | CorMedix Inc. | 95 | ±0 | Leader | +4% | +157%↓ | — | 73 | 2026-08-13 |
| KNSA | Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares | 95 | ±0 | Leader | +145% | +56% | +1565 bps | 93 | 2026-07-28 |
| LGND | Ligand Pharmaceuticals Inc. | 95 | ±0 | Leader | +825% | +34% | +5087 bps | 83 | 2026-08-07 |
| SEPN | Septerna, Inc. Common Stock | 95 | ±0 | Leader | loss narrowed 48% | >+999%↑ | — | 89 | 2026-08-10 |
| EVAX | Evaxion A/S American Depositary Share | 94 | ±0 | Leader | loss narrowed 90% | +125% | — | 26 | 2026-03-05 |
| PRTA | Prothena Corporation plc Ordinary Shares | 94 | -1 | Leader | loss narrowed 85% | -77% | >+10,000 bps | 41 | 2026-08-06 |
| RANI | Rani Therapeutics Holdings, Inc. Class A Common StockObesity & Weight-Loss Therapeutics | 94 | ±0 | Leader | loss narrowed 78%↓ | — | — | 13 | 2026-08-13 |
| VIVS | VivoSim Labs, Inc. Common Stock | 94 | ±0 | Leader | — | — | — | 3 | 2026-08-12 |
| ALVO | Alvotech Ordinary Shares | 93 | ±0 | Leader | to profit | +20% | -88 bps | 88 | 2026-03-31 |
| ANIP | ANI Pharmaceuticals, Inc. | 93 | ±0 | Leader | +192% | +26% | +1334 bps | 41 | 2026-08-07 |
| CRON | Cronos Group Inc. Common Share | 93 | ±0 | Leader | to profit↑ | +58% | +4041 bps | 78 | 2026-08-06 |
| LLY | Eli Lilly & Co.Obesity & Weight-Loss TherapeuticsHuman Therapeutics | 93 | ±0 | Leader | +26% | +48% | +1051 bps | 66 | 2026-08-05 |
| ONC | BeOne Medicines Ltd. American Depositary Shares | 93 | -1 | Leader | +167% | +30% | +1727 bps | 68 | 2026-08-05 |
| RCKT | Rocket Pharmaceuticals, Inc. Common Stock | 93 | ±0 | Leader | to profit | — | — | 19 | 2026-08-10 |
| VCEL | Vericel Corporation | 93 | ±0 | Leader | to profit↑ | +22% | +547 bps | 69 | 2026-07-30 |
| ADAG | Adagene Inc. American Depositary Shares | 92 | ±0 | Leader | loss narrowed 49% | >+999% | — | 40 | 2026-04-01 |
| ALNY | Alnylam Pharmaceuticals, Inc.Human Therapeutics | 92 | ±0 | Leader | — | +67%↓ | — | 23 | 2026-07-30 |
| OMER | Omeros Corporation | 92 | ±0 | Leader | to profit↓ | — | — | 92 | 2026-08-12 |
| PHAT | Phathom Pharmaceuticals, Inc. Common Stock | 92 | ±0 | Leader | loss narrowed 80% | +88% | >+10,000 bps | 22 | 2026-07-30 |
| AGEN | Agenus Inc. | 91 | ±0 | Leader | loss narrowed 99% | +34% | >+10,000 bps | 97 | 2026-08-07 |
| BMEA | Biomea Fusion, Inc. Common Stock | 91 | ±0 | Leader | loss narrowed 76%↓ | — | — | 67 | 2026-08-05 |
| EDIT | Editas Medicine, Inc. Common Stock | 91 | ±0 | Leader | loss narrowed 76% | +232% | >+10,000 bps | 48 | 2026-08-05 |
| IMCR | Immunocore Holdings plc American Depositary SharesHuman Therapeutics | 91 | ±0 | Leader | loss narrowed 90% | +18% | +780 bps | 54 | 2026-08-06 |
| URGN | UroGen Pharma Ltd. Ordinary SharesHuman Therapeutics | 91 | ±0 | Leader33 | loss narrowed 73%↑ | +199%↑ | +9580 bps | 97 | 2026-08-05 |
| ATHE | Alterity Therapeutics Limited American Depositary Shares | 90 | ±0 | Leader | loss narrowed 63% | +89% | — | 69 | 2026-08-28 |
| INDV | Indivior Pharmaceuticals, Inc. Common Stock | 90 | ±0 | Leader | +600% | +14%↓ | +1347 bps | 57 | 2026-08-03 |
| INSM | Insmed, Inc.Human Therapeutics | 90 | ±0 | Leader33 | loss narrowed 96%↑ | +296%↑ | >+10,000 bps | 38 | 2026-08-06 |
| ALT | Altimmune, Inc. Common StockObesity & Weight-Loss Therapeutics | 89 | -1 | Leader | loss narrowed 56%↑ | +420% | — | 32 | 2026-08-12 |
| CRSP | CRISPR Therapeutics AGHuman Therapeutics | 89 | ±0 | Strong | loss narrowed 61%↑ | >+999%↑ | <-10,000 bps | 56 | 2026-08-03 |
| IOVA | Iovance Biotherapeutics, Inc. Common StockHuman Therapeutics | 89 | ±0 | Strong33 | loss narrowed 67%↑ | +66%↑ | +7730 bps | 94 | 2026-08-06 |
| MGNX | MacroGenics, Inc. | 89 | ±0 | Strong | to profit↑ | +48%↓ | +2285 bps | 73 | 2026-08-14 |
| NUVB | Nuvation Bio Inc. | 89 | ±0 | Leader | loss widened 6% | +556% | >+10,000 bps | 86 | 2026-08-06 |
| PALI | Palisade Bio, Inc. Common Stock | 89 | -1 | Leader | loss narrowed 91% | — | — | 50 | 2026-08-10 |
| PRME | Prime Medicine, Inc. Common Stock | 89 | ±0 | Leader | loss narrowed 41%↑ | -62%↓ | — | 33 | 2026-08-06 |
| ABVC | ABVC BioPharma, Inc. Common Stock | 88 | -1 | Strong | loss narrowed 77%↑ | -9% | — | 18 | 2026-08-12 |
| KRYS | Krystal Biotech, Inc. Common StockHuman Therapeutics | 88 | ±0 | Strong | +39% | +24% | +615 bps | 85 | 2026-08-03 |
| RIGL | Rigel Pharmaceuticals Inc. (New) | 88 | ±0 | Strong | -73%↓ | -23%↓ | -759 bps | 94 | 2026-08-04 |
| TARS | Tarsus Pharmaceuticals, Inc. Common StockHuman Therapeutics | 88 | ±0 | Strong | loss narrowed 10% | +69%↓ | +2517 bps | 70 | 2026-08-06 |
| VIR | Vir Biotechnology, Inc. Common Stock | 88 | -1 | Strong | to profit | >+999% | >+10,000 bps | 60 | 2026-08-05 |
| VTGN | Vistagen Therapeutics, Inc. Common Stock | 88 | -1 | Strong | loss narrowed 36%↑ | +505% | — | 7 | 2026-08-14 |
| ALGS | Aligos Therapeutics, Inc. Common Stock | 87 | -1 | Strong | loss narrowed 91% | -100% | — | 19 | 2026-08-06 |
| AUPH | Aurinia Pharmaceuticals Inc | 87 | ±0 | Strong | +75% | +19%↓ | +2840 bps | 62 | 2026-08-06 |
| GTBP | GT Biopharma Inc. Common Stock | 87 | ±0 | Strong | loss narrowed 99% | — | — | 12 | 2026-08-14 |
| ICCC | Immucell Corp | 87 | ±0 | Strong | +233%↑ | +12% | +647 bps | 90 | 2026-08-13 |
| JAZZ | Jazz Pharmaceuticals, Inc. | 87 | ±0 | Strong | to profit | +16% | +2662 bps | 82 | 2026-08-03 |
| PHAR | Pharming Group N.V. ADS, each representing 10 ordinary shares | 87 | ±0 | Strong | to profit | +27% | +977 bps | 17 | 2026-04-02 |
| QUCY | Quantum Cyber N.V. Ordinary Shares | 87 | ±0 | Strong | loss narrowed 48%↓ | +141%↑ | — | — | 2026-08-14 |
| ADMA | ADMA Biologics, Inc.Human Therapeutics | 86 | -1 | Strong | +14% | +2% | +1100 bps | 13 | 2026-08-05 |
| PTCT | PTC Therapeutics, Inc.Human Therapeutics | 86 | -1 | Strong | to profit | +102% | -2825 bps | 53 | 2026-07-30 |
| FBIO | Fortress Biotech, Inc. | 85 | ±0 | Strong | to loss | +19%↓ | >+10,000 bps | 25 | 2026-08-13 |
| HALO | Halozyme Therapeutics, Inc. | 85 | ±0 | Strong | +43%↑ | +48% | -2202 bps | 92 | 2026-08-06 |
| SNDX | Syndax Pharmaceuticals, Inc.Human Therapeutics | 85 | -1 | Strong | loss narrowed 34% | +92%↓ | >+10,000 bps | 23 | 2026-08-04 |
| HOWL | Werewolf Therapeutics, Inc. Common Stock | 84 | ±0 | Strong | to profit | — | — | 72 | 2026-07-31 |
| MNOV | Medicinova, Inc. | 84 | ±0 | Strong | loss narrowed 29% | +241% | — | 77 | 2026-08-13 |
| WVE | Wave Life Sciences Ltd. Ordinary Shares | 84 | ±0 | Strong | loss widened 10% | -74% | — | 6 | 2026-07-30 |
| AMRX | Amneal Pharmaceuticals, Inc. Class A Common Stock | 83 | ±0 | Strong | +157% | +10% | +137 bps | 84 | 2026-08-06 |
| CAMP | CAMP4 Therapeutics Corporation Common Stock | 83 | ±0 | Strong | loss narrowed 6% | +19% | — | 24 | 2026-08-13 |
| PRLD | Prelude Therapeutics Incorporated | 83 | ±0 | Strong | loss narrowed 66% | — | — | 77 | 2026-08-11 |
| BHST | BioHarvest Sciences Inc. Common Stock | 82 | ±0 | Strong | loss narrowed 25% | +37% | +1159 bps | 9 | 2026-03-31 |
| TLRY | Tilray Brands, Inc. Common Stock | 82 | ±0 | Strong | loss narrowed 70% | +25%↑ | >+10,000 bps | 12 | 2026-07-28 |
| DTIL | Precision BioSciences, Inc. Common Stock | 81 | ±0 | Strong | loss narrowed 41%↓ | -100% | — | 89 | 2026-08-06 |
| FHTX | Foghorn Therapeutics Inc. Common Stock | 81 | ±0 | Strong | loss narrowed 64%↑ | +113% | >+10,000 bps | 25 | 2026-08-06 |
| INMB | INmune Bio Inc. Common stock | 81 | ±0 | Strong | loss narrowed 95% | — | — | 93 | 2026-08-06 |
| NATR | Nature's Sunshine Products Inc. | 81 | ±0 | Strong | -32%↓ | +2% | +156 bps | 11 | 2026-08-06 |
| OCS | Oculis Holding AG Ordinary shares | 81 | ±0 | Strong | loss narrowed 11% | +75% | — | 8 | 2026-03-04 |
| RNXT | RenovoRx, Inc. Common Stock | 81 | -1 | Strong | loss narrowed 25% | +115%↓ | — | 97 | 2026-08-13 |
| ABBV | ABBVIE INC.Human Therapeutics | 80 | -1 | Strong | +290% | +10% | — | 65 | 2026-08-03 |
| BEAM | Beam Therapeutics Inc. Common StockHuman Therapeutics | 80 | ±0 | Strong | loss widened 18%↓ | -94% | >+10,000 bps | 40 | 2026-08-04 |
| ELAN | Elanco Animal Health Incorporated Common Stock | 80 | ±0 | Strong | +450%↑ | +10% | -1653 bps | 45 | 2026-08-05 |
| EOLS | Evolus, Inc. Common Stock | 80 | ±0 | Strong | loss narrowed 56% | +21% | +963 bps | 90 | 2026-08-05 |
| GERN | Geron Corp | 80 | ±0 | Strong | loss widened 0% | +17%↓ | — | 28 | 2026-08-05 |
| KYMR | Kymera Therapeutics, Inc. Common StockHuman Therapeutics | 80 | ±0 | Strong33 | loss narrowed 35%↑ | +466%↑ | >+10,000 bps | 89 | 2026-08-05 |
| STTK | Shattuck Labs, Inc. Common Stock | 80 | ±0 | Strong | loss narrowed 50%↓ | — | — | 56 | 2026-08-11 |
| ASMB | Assembly Biosciences, Inc | 79 | ±0 | Strong | loss narrowed 85% | +39% | >+10,000 bps | 56 | 2026-08-13 |
| AUTL | Autolus Therapeutics plc American Depositary Share | 79 | ±0 | Strong | loss narrowed 17%↑ | +118%↓ | >+10,000 bps | 79 | 2026-08-11 |
| COLL | Collegium Pharmaceutical, Inc. Common Stock | 79 | -1 | Strong | to loss | +6%↓ | +113 bps | 15 | 2026-08-06 |
| DYAI | Dyadic International, Inc. | 79 | ±0 | Strong | loss widened 0% | -1% | — | 14 | 2026-08-12 |
| ARDX | Ardelyx, Inc. | 78 | ±0 | Strong | loss narrowed 12%↑ | +24% | +260 bps | 13 | 2026-08-06 |
| CBIO | Crescent Biopharma, Inc. Common Stock | 78 | -1 | Strong | loss narrowed 76%↑ | — | — | 93 | 2026-07-30 |
| COYA | Coya Therapeutics, Inc. Common Stock | 78 | ±0 | Strong | loss narrowed 22% | +49% | — | 38 | 2026-08-11 |
| HYFT | MindWalk Holdings Corp. Common Stock | 78 | ±0 | Strong | loss narrowed 88%↑ | -32% | — | 54 | 2026-07-23 |
| INVA | Innoviva, Inc. Common Stock | 78 | ±0 | Strong | to loss↓ | +19% | +407 bps | 39 | 2026-08-05 |
| PLRX | Pliant Therapeutics, Inc. Common Stock | 78 | -1 | Strong | loss narrowed 49% | — | — | 31 | 2026-08-11 |
| RNTX | Rein Therapeutics, Inc. Common Stock | 78 | ±0 | Strong | loss narrowed 64% | — | — | 14 | 2026-08-14 |
| AQST | Aquestive Therapeutics, Inc. Common Stock | 77 | ±0 | Strong | loss widened 29% | +38% | +2167 bps | 71 | 2026-08-11 |
| DARE | Dare Bioscience, Inc. Common Stock | 77 | -1 | Strong | loss narrowed 56%↓ | — | — | 9 | 2026-08-13 |
| RFL | Rafael Holdings, Inc. Class B Common Stock | 77 | ±0 | Strong | loss narrowed 58% | -51% | — | 92 | 2026-06-11 |
| BBIO | BridgeBio Pharma, Inc. Common Stock | 76 | ±0 | Strong | loss narrowed 18% | +120% | >+10,000 bps | 52 | 2026-08-10 |
| CDIO | Cardio Diagnostics Holdings Inc. Common stock | 76 | -1 | Strong | loss narrowed 47%↑ | -28% | — | 8 | 2026-08-07 |
| DERM | Journey Medical Corporation Common Stock | 76 | ±0 | Strong | loss narrowed 94%↑ | +19%↓ | +788 bps | 32 | 2026-08-12 |
| FDMT | 4D Molecular Therapeutics, Inc. Common Stock | 76 | ±0 | Strong | loss widened 6% | >+999% | — | 92 | 2026-08-13 |
| GOSS | Gossamer Bio, Inc. Common Stock | 76 | -1 | Strong | loss narrowed 53%↑ | -20% | +5021 bps | 5 | 2026-08-13 |
| LNTH | Lantheus Holdings, Inc | 76 | ±0 | Strong | -1%↓ | +3% | -935 bps | 76 | 2026-08-06 |
| ALLO | Allogene Therapeutics, Inc. Common Stock | 75 | -1 | Strong | loss narrowed 43% | — | — | 16 | 2026-08-12 |
| ATYR | aTyr Pharma, Inc. Common Stock | 75 | -1 | Strong | loss narrowed 50%↑ | — | — | 9 | 2026-08-07 |
| BFRI | Biofrontera Inc. Common Stock | 75 | ±0 | Strong | loss narrowed 91%↑ | +33% | +2737 bps | 94 | 2026-08-13 |
| QGEN | QIAGEN N.V. | 75 | ±0 | Strong | +424% | +6% | +1735 bps | 53 | 2026-03-20 |
| RPRX | Royalty Pharma plc Class A Ordinary Shares | 75 | -1 | Strong | -43% | +16%↑ | -2023 bps | 80 | 2026-08-05 |
| SNTI | Senti Biosciences Holdings, Inc. Common Stock | 75 | -1 | Strong | loss narrowed 27%↓ | — | — | 5 | 2026-08-14 |
| AVIR | Atea Pharmaceuticals, Inc. Common Stock | 74 | -1 | Strong | loss narrowed 3% | +622% | — | 31 | 2026-08-12 |
| AXSM | Axsome Therapeutics, Inc | 74 | ±0 | Strong | loss widened 2% | +46%↓ | +2229 bps | 84 | 2026-08-10 |
| CLLS | Cellectis S.A. American Depositary Shares | 74 | ±0 | Strong | loss narrowed 14% | +107% | — | 27 | 2026-03-20 |
| HRMY | Harmony Biosciences Holdings, Inc. Common Stock | 74 | -1 | Strong | +88%↑ | +30% | -469 bps | 88 | 2026-08-04 |
| INM | InMed Pharmaceuticals Inc. Common Shares | 74 | -2 | Strong | loss narrowed 86% | -26%↓ | — | 93 | new filing |
| RYTM | Rhythm Pharmaceuticals, Inc. Common StockHuman Therapeutics | 74 | ±0 | Strong | loss narrowed 3%↑ | +47% | +2991 bps | 67 | 2026-08-04 |
| BCDA | BioCardia, Inc. Common Stock | 73 | ±0 | Strong | loss narrowed 68% | — | — | 31 | 2026-08-12 |
| EXEL | Exelixis IncHuman Therapeutics | 73 | ±0 | Strong | +26%↓ | +11%↑ | +851 bps | 86 | 2026-08-05 |
| JAGX | Jaguar Health, Inc. | 73 | -19 | Strong | loss widened 53%↓ | -59% | >+10,000 bps | 1 | 2026-08-19 |
| MDGL | Madrigal Pharmaceuticals, Inc. Common StockHuman Therapeutics | 73 | ±0 | Strong | loss widened 5% | +71%↓ | +3497 bps | 78 | 2026-07-30 |
| SLS | SELLAS Life Sciences Group, Inc. Common Stock | 73 | -1 | Strong | loss narrowed 29% | — | — | 98 | 2026-08-11 |
| KTTA | Pasithea Therapeutics Corp. Common Stock | 72 | ±0 | Strong | loss narrowed 77% | >+999% | — | 15 | 2026-08-14 |
| LCTX | Lineage Cell Therapeutics, Inc. | 72 | -1 | Strong | loss narrowed 77%↑ | -61%↓ | >+10,000 bps | 14 | 2026-08-06 |
| MRKR | Marker Therapeutics, Inc. Common Stock | 72 | -1 | Strong | loss narrowed 69% | +115% | — | 33 | 2026-08-14 |
| VRDN | Viridian Therapeutics, Inc. Common Stock | 72 | -1 | Strong | loss widened 21% | +279%↑ | — | 24 | 2026-08-06 |
| ACIU | AC Immune SA | 71 | ±0 | Strong | loss narrowed 9% | +90% | — | 34 | 2026-03-13 |
| AGIO | Agios Pharmaceuticals, Inc. | 71 | ±0 | Strong33 | loss narrowed 12%↑ | +259%↑ | >+10,000 bps | 74 | 2026-07-30 |
| IXHL | Incannex Healthcare Limited American Depositary Shares | 71 | ±0 | Strong | loss widened 17% | +617% | — | 11 | 2026-05-15 |
| NRXP | NRX Pharmaceuticals, Inc. Common Stock | 71 | ±0 | Strong | loss narrowed 55%↓ | — | — | 95 | 2026-08-14 |
| OTLK | Outlook Therapeutics, Inc. Common Stock | 71 | ±0 | Strong | loss narrowed 73% | — | — | 91 | 2026-08-18 |
| QURE | uniQure N.V.Human Therapeutics | 71 | ±0 | Strong | loss widened 4% | +127% | <-10,000 bps | 98 | 2026-07-29 |
| SNDL | Sundial Growers Inc. Common Shares | 71 | ±0 | Strong | loss narrowed 83% | +3% | +1001 bps | 33 | 2026-03-12 |
| AZN | AstraZeneca PLCObesity & Weight-Loss TherapeuticsHuman Therapeutics | 70 | ±0 | Strong | +27% | +12% | — | 28 | 2026-02-24 |
| GANX | Gain Therapeutics, Inc. Common Stock | 70 | -1 | Strong | loss narrowed 42%↑ | — | — | 13 | 2026-08-11 |
| SBFM | Sunshine Biopharma Inc. | 70 | -1 | Strong | loss widened 40% | -2%↑ | +136 bps | 2 | 2026-08-13 |
| CNTB | Connect Biopharma Holdings Limited Ordinary Shares | 69 | ±0 | Average | loss widened 17% | >+999% | — | 17 | 2026-08-12 |
| IFRX | InflaRx N.V. Common Stock | 69 | -1 | Strong | loss narrowed 13%↑ | +520% | — | 97 | 2026-03-20 |
| PAHC | Phibro Animal Health Corporation Class A | 69 | -21 | Average | +21% | +5%↓ | +428 bps | 21 | 2026-08-26 |
| PRQR | ProQR Therapeutics N.V. Ordinary Shares | 69 | ±0 | Average | loss narrowed 20%↑ | +9%↑ | <-10,000 bps | 60 | 2026-03-12 |
| TECH | Bio-Techne Corp. | 69 | +30 | Average | to profit↑ | +1% | +1235 bps | 85 | 2026-08-24 |
| FTLF | FitLife Brands, Inc. Common Stock | 68 | ±0 | Average | +11% | +65% | -744 bps | 14 | 2026-08-13 |
| HCM | HUTCHMED (China) Limited American Depositary Shares | 68 | ±0 | Average | >+999% | -13% | -20 bps | 36 | 2026-03-05 |
| ABEO | Abeona Therapeutics Inc. Common Stock | 67 | -1 | Average | to loss | >+999% | — | 63 | 2026-08-13 |
| CYTK | Cytokinetics Inc.Human Therapeutics | 67 | ±0 | Average | loss widened 34%↓ | -57% | <-10,000 bps | 70 | 2026-08-06 |
| HURA | TuHURA Biosciences, Inc. Common Stock | 67 | -1 | Average | loss narrowed 33%↑ | — | — | 52 | 2026-08-14 |
| IVVD | Invivyd, Inc. Common Stock | 67 | ±0 | Average | loss widened 17%↓ | +21%↓ | +5285 bps | 8 | 2026-08-13 |
| ADPT | Adaptive Biotechnologies Corporation Common Stock | 66 | -1 | Average | loss widened 47%↓ | +22%↓ | +4686 bps | 94 | 2026-08-04 |
| GDTC | CytoMed Therapeutics Limited Ordinary Shares | 66 | ±0 | Average | loss widened 55% | +367% | — | 23 | 2026-03-31 |
| GSK | GSK plc American Depositary Shares (Each representing two Ordinary Shares)Human Therapeutics | 66 | ±0 | Average | +123% | +4% | +1147 bps | 33 | 2026-07-28 |
| PHIO | Phio Pharmaceuticals Corp. Common Stock | 66 | -1 | Average | loss narrowed 20% | — | — | 26 | 2026-08-06 |
| SCNX | Scienture Holdings, Inc. Common Stock | 66 | ±0 | Average | loss narrowed 85% | — | — | 23 | 2026-08-13 |
| SDGR | Schrodinger, Inc. Common Stock | 65 | -1 | Average | to profit | +8% | +2185 bps | 90 | 2026-08-05 |
| VRTX | Vertex Pharmaceuticals IncHuman Therapeutics | 65 | ±0 | Average | +8% | +12% | +359 bps | 56 | 2026-08-04 |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 64 | -1 | Average | loss narrowed 37% | +578%↑ | — | 33 | 2026-08-10 |
| AMGN | Amgen IncObesity & Weight-Loss TherapeuticsHuman Therapeutics | 63 | ±0 | Average | +65% | +10% | +653 bps | 51 | 2026-08-05 |
| KPRX | Kiora Pharmaceuticals, Inc. Common Stock | 63 | ±0 | Average | loss narrowed 37%↑ | — | — | 73 | 2026-08-07 |
| RARE | Ultragenyx Pharmaceutical Inc.Human Therapeutics | 63 | ±0 | Average | loss narrowed 23% | +29% | +914 bps | 15 | 2026-08-05 |
| RCUS | Arcus Biosciences, Inc. | 63 | ±0 | Average | to loss↓ | +313%↑ | — | 60 | 2026-08-05 |
| RLAY | Relay Therapeutics, Inc. Common Stock | 63 | ±0 | Average | loss widened 0%↓ | -48%↑ | — | 94 | 2026-08-06 |
| IDXX | Idexx Laboratories Inc | 62 | ±0 | Average | +18% | +10%↓ | +95 bps | 30 | 2026-08-04 |
| NNVC | NanoViricides Inc. | 62 | ±0 | Average | loss narrowed 36% | — | — | 34 | 2026-05-15 |
| PCRX | Pacira BioSciences, Inc. Common Stock | 62 | -1 | Average | to profit↑ | +6% | +1744 bps | 64 | 2026-08-04 |
| BIOA | BioAge Labs, Inc. Common StockObesity & Weight-Loss Therapeutics | 61 | ±0 | Average | loss narrowed 3%↑ | +2%↓ | — | 8 | 2026-08-05 |
| CGON | CG Oncology, Inc. Common stock | 61 | ±0 | Average | loss widened 67%↓ | — | — | 65 | 2026-08-06 |
| HYPD | Hyperion DeFi, Inc. Common Stock | 61 | ±0 | Average | to profit↑ | — | — | 59 | 2026-08-13 |
| MRNA | Moderna, Inc. Common StockHuman Therapeutics | 61 | ±0 | Average | loss narrowed 8% | +2% | -4268 bps | 98 | 2026-07-31 |
| BMY | Bristol-Myers Squibb Co.Human Therapeutics | 60 | -1 | Average | +153% | +6%↑ | +1039 bps | 59 | 2026-07-30 |
| KURA | Kura Oncology, Inc. | 60 | ±0 | Average | loss widened 3%↑ | +37%↑ | — | 79 | 2026-08-12 |
| PGEN | Precigen, Inc. Common Stock | 60 | ±0 | Average | to profit↑ | >+999%↑ | — | 96 | 2026-08-04 |
| SPRY | ARS Pharmaceuticals, Inc. Common Stock | 60 | -1 | Average | loss widened 37%↑ | +114% | <-10,000 bps | 13 | 2026-08-13 |
| TKNO | Alpha Teknova, Inc. Common Stock | 60 | ±0 | Average33 | loss narrowed 14%↑ | +18%↑ | +1882 bps | 98 | 2026-08-06 |
| VSTM | Verastem, Inc. | 60 | ±0 | Average | loss narrowed 44%↓ | >+999% | — | 77 | 2026-08-06 |
| ACOG | Alpha Cognition Inc. Common Stock | 59 | ±0 | Average | loss narrowed 38% | +268%↑ | — | 91 | 2026-08-13 |
| LFCR | Lifecore Biomedical, Inc. Common Stock | 59 | ±0 | Average | loss widened 111%↓ | +294%↑ | +3053 bps | 13 | 2026-08-05 |
| SCNI | Scinai Immunotherapeutics Ltd. American Depositary Shares | 59 | ±0 | Average | to loss | >+999% | — | 4 | 2026-04-01 |
| SXTP | 60 Degrees Pharmaceuticals, Inc. Common Stock | 59 | -1 | Average | loss narrowed 28% | +106% | — | 5 | 2026-08-14 |
| ARWR | Arrowhead Research CorporationObesity & Weight-Loss TherapeuticsHuman Therapeutics | 58 | -1 | Average | loss widened 8% | +171% | -1498 bps | 88 | 2026-08-04 |
| KMDA | Kamada Ltd | 58 | -1 | Average | 0%↓ | +13% | — | 40 | 2026-03-11 |
| ACAD | Acadia Pharmaceuticals Inc.Human Therapeutics | 57 | -1 | Average | +13% | +16%↑ | -1566 bps | 80 | 2026-08-05 |
| GELS | Gelteq Limited Ordinary Shares | 57 | ±0 | Average | loss widened 64% | +107% | — | 59 | 2025-11-17 |
| IMMP | Immutep Limited American Depositary Shares | 57 | -1 | Average | loss widened 19% | +32% | — | 2 | 2025-10-24 |
| MIST | Milestone Pharmaceuticals Inc. Common Shares | 57 | ±0 | Average | loss widened 5% | — | — | 14 | 2026-08-12 |
| UPB | Upstream Bio, Inc. Common Stock | 57 | -1 | Average | loss narrowed 1%↑ | -18% | — | 14 | 2026-08-11 |
| XBIO | Xenetic Biosciences, Inc. | 57 | ±0 | Average | loss narrowed 9%↓ | +12% | — | 92 | 2026-08-06 |
| COCP | Cocrystal Pharma, Inc. Common Stock | 56 | ±0 | Average | loss widened 15%↓ | — | — | 73 | 2026-08-13 |
| RLYB | Rallybio Corporation Common Stock | 56 | ±0 | Average | to profit | -100%↓ | — | 93 | 2026-08-06 |
| CYPH | Cypherpunk Technologies Inc. Common Stock | 55 | ±0 | Average | to profit | 0% | — | 99 | 2026-08-12 |
| IKT | Inhibikase Therapeutics, Inc. Common Stock | 55 | -1 | Average | loss widened 0% | — | — | 69 | 2026-08-11 |
| LAB | Standard BioTools Inc. Common Stock | 55 | ±0 | Average | loss narrowed 22% | -8%↑ | -5986 bps | 19 | 2026-08-05 |
| XLO | Xilio Therapeutics, Inc. Common Stock | 55 | +1 | Average | loss widened 106%↑ | +131%↓ | — | 72 | 2026-08-12 |
| CHRS | Coherus Oncology, Inc. Common Stock | 54 | ±0 | Average | to loss | +40% | <-10,000 bps | 22 | 2026-08-05 |
| IBRX | ImmunityBio, Inc. Common Stock | 54 | ±0 | Average | loss widened 120% | +94%↓ | >+10,000 bps | 40 | 2026-08-04 |
| UPC | Universe Pharmaceuticals Inc. Class A Ordinary Shares | 53 | ±0 | Average | loss narrowed 99% | >+999% | +1850 bps | — | 2026-01-29 |
| XFOR | X4 Pharmaceuticals, Inc. Common Stock | 52 | ±0 | Average | loss narrowed 96% | +346% | <-10,000 bps | 24 | 2026-08-06 |
| ATAI | AtaiBeckley Inc. Common Stock | 51 | ±0 | Average | loss widened 213% | >+999% | — | 95 | 2026-08-11 |
| CGC | Canopy Growth Corporation Common Shares | 51 | ±0 | Average | — | — | >+10,000 bps | 32 | 2026-08-07 |
| ENSC | Ensysce Biosciences, Inc. Common Stock | 51 | -1 | Average | loss narrowed 75% | -15% | — | 66 | 2026-08-13 |
| IMCC | IM Cannabis Corp. Common Shares | 51 | -1 | Average | loss narrowed 41% | +1% | -223 bps | 2 | 2026-03-30 |
| LXRX | Lexicon Pharmaceuticals, Inc. | 51 | ±0 | Average | to loss | -98% | >+10,000 bps | 71 | 2026-08-06 |
| NVO | Novo-Nordisk A/SObesity & Weight-Loss TherapeuticsHuman Therapeutics | 51 | -1 | Average | +2% | +6% | -289 bps | 67 | 2026-02-04 |
| REGN | Regeneron Pharmaceuticals IncObesity & Weight-Loss TherapeuticsHuman Therapeutics | 51 | ±0 | Average | -5% | +17% | -228 bps | 53 | 2026-07-30 |
| TVTX | Travere Therapeutics, Inc. Common StockHuman Therapeutics | 51 | -1 | Average | loss widened 164%↓ | +48%↓ | +4474 bps | 98 | 2026-08-04 |
| PBH | Prestige Consumer Healthcare Inc. | 50 | ±0 | Average | -36% | +6% | -378 bps | 21 | 2026-08-06 |
| MTEX | Mannatech Inc. | 49 | ±0 | Average | to profit | +4%↑ | +295 bps | 77 | 2026-08-12 |
| NAGE | Niagen Bioscience, Inc. Common Stock | 49 | ±0 | Average | -75% | -4%↓ | -612 bps | 14 | 2026-08-04 |
| MNKD | Mannkind Corporation | 48 | -1 | Average | to loss↑ | +43% | -1982 bps | 85 | 2026-08-05 |
| OPK | Opko Health Inc. | 48 | -1 | Average33 | loss narrowed 95%↑ | +4%↑ | +1379 bps | 81 | 2026-07-27 |
| PPBT | Purple Biotech Ltd. American Depositary Shares | 48 | ±0 | Average | -99% | 0% | — | 8 | 2026-03-19 |
| TLX | Telix Pharmaceuticals Limited American Depositary Shares | 48 | ±0 | Average | to loss | +56% | — | 92 | 2026-02-20 |
| ACB | Aurora Cannabis Inc. Common Shares | 47 | -1 | Average | -89% | +27% | +1863 bps | 55 | 2026-06-11 |
| SLN | Silence Therapeutics Plc American Depository Share | 47 | -1 | Average | loss narrowed 53%↑ | -100% | — | 96 | 2026-08-10 |
| CCCC | C4 Therapeutics, Inc. | 46 | ±0 | Average33 | loss narrowed 51%↑ | +3%↑ | +6830 bps | 67 | 2026-08-11 |
| EQ | Equillium, Inc. Common Stock | 46 | ±0 | Average | loss narrowed 75% | -52%↓ | — | 76 | 2026-08-13 |
| NNNN | Anbio Biotechnology Class A Ordinary Shares | 46 | -1 | Average | +163% | +6% | — | 5 | 2026-04-07 |
| PLUR | Pluri Inc. Common Stock | 46 | ±0 | Average | loss narrowed 41% | -61% | — | 7 | 2026-05-14 |
| SCYX | SCYNEXIS, Inc. | 45 | ±0 | Average | to profit | -83% | — | 16 | 2026-08-10 |
| SRZN | Surrozen, Inc. Common | 45 | ±0 | Average | to loss | +409% | <-10,000 bps | 20 | 2026-08-06 |
| UTHR | United Therapeutics CorpHuman Therapeutics | 45 | ±0 | Average | +13% | -2%↓ | -261 bps | 39 | 2026-08-05 |
| IPSC | Century Therapeutics, Inc. Common Stock | 44 | -1 | Average | loss narrowed 55% | -100% | — | 19 | 2026-08-12 |
| JANX | Janux Therapeutics, Inc. Common Stock | 44 | -1 | Average | loss narrowed 36%↑ | — | — | 79 | 2026-08-06 |
| RGNX | REGENXBIO Inc. | 44 | +1 | Average | to profit | +406% | +1158 bps | 38 | 2026-08-06 |
| ADCT | ADC Therapeutics SAHuman Therapeutics | 43 | -1 | Average | loss narrowed 78% | +3%↓ | +7904 bps | 4 | 2026-08-13 |
| ERNA | Ernexa Therapeutics Inc. Common Stock | 43 | ±0 | Average | loss widened 457% | — | — | 12 | 2026-08-06 |
| LGVN | Longeveron Inc. Common Stock | 43 | -1 | Average | loss narrowed 42% | -9% | — | 27 | 2026-08-12 |
| MCRB | Seres Therapeutics, Inc. | 43 | ±0 | Average | to profit↑ | — | — | 12 | 2026-08-05 |
| BDRX | Biodexa Pharmaceuticals plc American Depositary Shs | 42 | ±0 | Average | loss narrowed 90% | -45% | — | 3 | 2026-03-27 |
| ROIV | Roivant Sciences Ltd. Common Shares | 42 | -1 | Average | loss narrowed 21% | -34% | — | 87 | 2026-08-06 |
| ANIX | Anixa Biosciences, Inc. | 41 | -17 | Average | loss widened 14% | — | — | 40 | new filing |
| BGM | BGM Group Ltd. Class A Ordinary Shares | 41 | ±0 | Average | loss narrowed 10% | +51% | -3093 bps | 5 | 2026-07-21 |
| BMRN | BioMarin Pharmaceuticals IncHuman Therapeutics | 41 | -1 | Average | -81% | +20% | -2095 bps | 62 | 2026-08-06 |
| CUE | Cue Biopharma, Inc. | 41 | ±0 | Average | loss widened 999%↓ | +167%↓ | — | 98 | 2026-08-14 |
| MRVI | Maravai LifeSciences Holdings, Inc. Class A Common Stock | 41 | -1 | Average | loss narrowed 70% | +9% | +8892 bps | 96 | 2026-08-07 |
| TWST | Twist Bioscience Corporation Common StockGenomics & Precision-Medicine Tools | 41 | ±0 | Average | to loss↓ | +23%↑ | +572 bps | 98 | 2026-08-03 |
| CORT | Corcept Therapeutics Inc.Human Therapeutics | 40 | ±0 | Average | +24% | +32% | -1347 bps | 99 | 2026-07-29 |
| EVMN | Evommune, Inc. | 40 | ±0 | Average | loss narrowed 90%↓ | — | — | 9 | 2026-08-06 |
| STOK | Stoke Therapeutics, Inc. Common Stock | 40 | ±0 | Average | loss widened 132%↑ | -33% | <-10,000 bps | 23 | 2026-08-03 |
| VNRX | VolitionRx Limited | 40 | ±0 | Average | loss widened 999% | -2% | — | 2 | 2026-08-13 |
| CLNN | Clene Inc. Common Stock | 39 | ±0 | Average | loss widened 38% | +233% | — | 16 | 2026-08-14 |
| CPHI | China Pharma Holdings, Inc. | 39 | -1 | Average | loss narrowed 75% | -8% | — | — | 2026-08-14 |
| DBVT | DBV Technologies S.A. | 39 | -1 | Average | loss narrowed 61%↑ | -52%↓ | — | 15 | 2026-07-16 |
| BLRX | BioLineRX Ltd | 38 | ±0 | Average | to profit | -96% | — | 45 | 2026-03-23 |
| DNLI | Denali Therapeutics Inc. Common StockHuman Therapeutics | 38 | ±0 | Average | loss narrowed 6% | — | — | 47 | 2026-08-06 |
| LEXX | Lexaria Bioscience Corp. Common Stock | 38 | -1 | Average | loss narrowed 62%↑ | -100% | — | 7 | 2026-07-13 |
| OCGN | Ocugen, Inc. Common Stock | 38 | -1 | Average | loss widened 40% | +8% | — | 8 | 2026-08-06 |
| RDY | Dr. Reddy's Laboratories Limited American Depositary Shares | 38 | -1 | Average | -80% | +17% | -219 bps | 26 | 2026-05-29 |
| SUPN | Supernus Pharmaceuticals, Inc. | 38 | -1 | Average | to loss | +32% | -2535 bps | 24 | 2026-08-03 |
| ZLAB | Zai Lab Limited American Depositary SharesHuman Therapeutics | 38 | ±0 | Average | loss widened 25% | -3% | -142 bps | 80 | 2026-08-06 |
| DSGN | Design Therapeutics, Inc. Common Stock | 37 | -1 | Average | loss narrowed 6% | — | — | 90 | 2026-08-03 |
| ENTA | Enanta Pharmaceuticals, Inc | 37 | -1 | Average | loss narrowed 21%↓ | -22%↓ | >+10,000 bps | 36 | 2026-08-12 |
| IONS | Ionis Pharmaceuticals, Inc. Common StockHuman Therapeutics | 37 | -1 | Average | to loss | -41% | — | 22 | 2026-07-29 |
| MIRM | Mirum Pharmaceuticals, Inc. Common StockHuman Therapeutics | 37 | ±0 | Average | loss widened 783% | +38%↓ | <-10,000 bps | 63 | 2026-08-05 |
| XERS | Xeris Biopharma Holdings, Inc. Common Stock | 37 | ±0 | Average | loss widened 999%↓ | +29%↓ | +1490 bps | 84 | 2026-08-06 |
| ALKS | Alkermes Inc. plcHuman Therapeutics | 36 | -1 | Average | -100% | +27% | -1783 bps | 93 | 2026-07-28 |
| HUMA | Humacyte, Inc. Common Stock | 36 | ±0 | Average | loss narrowed 33% | +35%↑ | — | 9 | 2026-08-12 |
| APRE | Aprea Therapeutics, Inc. Common stock | 35 | ±0 | Average | loss narrowed 87%↑ | -98% | — | 50 | 2026-08-12 |
| IBIO | iBio, Inc. Common Stock | 35 | -1 | Average | loss narrowed 81% | -100% | — | 10 | 2026-08-28 |
| CYRX | CryoPort, Inc. Common Stock | 34 | ±0 | Average | to loss↓ | +8% | +440 bps | 96 | 2026-08-06 |
| HROW | Harrow, Inc. Common Stock | 34 | ±0 | Average | to loss↓ | +11% | -732 bps | 47 | 2026-08-10 |
| SNGX | Soligenix, Inc. Common Stock | 34 | ±0 | Average | loss narrowed 85% | -100% | — | 5 | 2026-08-07 |
| TPST | Tempest Therapeutics, Inc. Common Stock | 33 | ±0 | Average | loss narrowed 84%↑ | -2% | — | 6 | 2026-08-13 |
| ZTS | ZOETIS INC. | 33 | -1 | Average | +2% | 0%↓ | -97 bps | 14 | 2026-08-06 |
| ALXO | ALX Oncology Holdings Inc. Common Stock | 32 | ±0 | Average | loss narrowed 73%↑ | — | — | 34 | 2026-08-06 |
| AMPH | Amphastar Pharmaceuticals, Inc. | 32 | ±0 | Average | +5% | +5%↑ | -948 bps | 79 | 2026-08-06 |
| CRBU | Caribou Biosciences, Inc. Common Stock | 32 | -1 | Average | loss narrowed 59%↑ | -44%↓ | — | 18 | 2026-08-13 |
| GOVX | GeoVax Labs, Inc. New | 32 | ±0 | Average | loss widened 177% | -100% | — | 4 | 2026-07-27 |
| JNJ | Johnson & Johnson | 32 | ±0 | Average | -1% | +7% | -913 bps | 63 | 2026-07-23 |
| KZIA | Kazia Therapeutics Limited American Depositary Shares | 32 | ±0 | Average | loss narrowed 63% | -98% | — | 85 | 2025-11-07 |
| SABS | SAB Biotherapeutics, Inc. Common Stock | 32 | ±0 | Average | loss narrowed 74% | -62% | — | 22 | 2026-08-06 |
| TAK | Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)Human Therapeutics | 32 | ±0 | Average | -26% | +7% | +246 bps | 49 | 2026-06-17 |
| CSBR | Champions Oncology, Inc. | 31 | ±0 | Average | loss narrowed 58% | +12% | -991 bps | 32 | 2026-07-27 |
| PYXS | Pyxis Oncology, Inc. Common Stock | 31 | -1 | Average | loss widened 33%↓ | — | — | 97 | 2026-08-13 |
| RGEN | Repligen Corp | 31 | -1 | Average | -65%↓ | +12%↓ | +1177 bps | 87 | 2026-07-29 |
| AMRN | Amarin Corp Plc | 30 | -1 | Average | loss narrowed 33% | -42% | +2845 bps | 32 | 2026-07-29 |
| ARMP | Armata Pharmaceuticals, Inc. Common Stock | 30 | -1 | Average | loss narrowed 40%↑ | +16% | — | 9 | 2026-08-12 |
| ELUT | Elutia Inc. Class A Common Stock | 30 | ±0 | Average | loss narrowed 35%↑ | -61%↓ | — | 21 | 2026-08-14 |
| ENTX | Entera Bio Ltd. Ordinary Shares | 30 | ±0 | Average | +133%↑ | — | — | 96 | 2026-08-07 |
| IMDX | Insight Molecular Diagnostics Inc. Common Stock | 30 | ±0 | Average | loss widened 3%↓ | -54% | — | 22 | 2026-08-10 |
| KRRO | Korro Bio, Inc. Common Stock | 30 | ±0 | Average | loss narrowed 61%↑ | -100% | — | 64 | 2026-08-06 |
| RXRX | Recursion Pharmaceuticals, Inc. Class A Common StockHuman Therapeutics | 30 | ±0 | Laggard | loss narrowed 39%↓ | -60%↓ | +1409 bps | 38 | 2026-08-05 |
| SRPT | Sarepta Therapeutics,, Inc. Common StockHuman Therapeutics | 30 | ±0 | Laggard | to loss | -36% | — | 71 | 2026-08-05 |
| BYSI | BeyondSpring Inc. Ordinary Shares | 29 | ±0 | Laggard | loss narrowed 80% | — | — | 10 | 2026-08-14 |
| GNLX | Genelux Corporation Common Stock | 29 | ±0 | Laggard | loss widened 5% | — | — | 35 | 2026-08-13 |
| PULM | Pulmatrix, Inc. Common Stock | 29 | ±0 | Laggard | loss narrowed 31%↓ | -100%↓ | — | 16 | 2026-08-13 |
| ACET | Adicet Bio, Inc. Common Stock | 28 | ±0 | Laggard | loss widened 485%↑ | -100% | — | 81 | 2026-08-05 |
| ELOX | Eloxx Pharmaceuticals, Inc. Common Stock | 28 | ±0 | Laggard | loss narrowed 42% | -100% | — | 99 | 2026-08-11 |
| INO | Inovio Pharmaceuticals, Inc. | 28 | ±0 | Laggard | loss narrowed 89% | — | — | 22 | 2026-08-12 |
| LENZ | LENZ Therapeutics, Inc. Common Stock | 28 | ±0 | Laggard | loss widened 92%↑ | +10% | — | 7 | 2026-08-11 |
| NTLA | Intellia Therapeutics, IncHuman Therapeutics | 28 | ±0 | Laggard | loss narrowed 18%↓ | -46%↓ | >+10,000 bps | 38 | 2026-08-06 |
| SRRK | Scholar Rock Holding Corporation Common StockObesity & Weight-Loss Therapeutics | 28 | ±0 | Laggard | loss narrowed 14% | — | — | 82 | 2026-08-06 |
| VRCA | Verrica Pharmaceuticals Inc. Common Stock | 28 | ±0 | Laggard | to loss | -54%↓ | >+10,000 bps | 25 | 2026-08-06 |
| EBS | Emergent Biosolutions, Inc. | 27 | ±0 | Laggard | loss widened 999% | +66% | -2108 bps | 20 | 2026-08-06 |
| GRCE | Grace Therapeutics, Inc. Common Stock | 27 | ±0 | Laggard | loss narrowed 41% | -100% | — | 12 | 2026-08-13 |
| MREO | Mereo BioPharma Group plc American Depositary Shares | 27 | -1 | Laggard | loss narrowed 50% | -100% | — | 14 | 2026-08-11 |
| ALEC | Alector, Inc. Common Stock | 26 | -1 | Laggard | loss narrowed 30% | -58%↑ | <-10,000 bps | 39 | 2026-08-06 |
| BNTC | Benitec Biopharma Inc. Common Stock | 26 | -1 | Laggard | loss widened 0%↑ | — | — | 48 | 2026-05-14 |
| CRDF | Cardiff Oncology, Inc. Common Stock | 26 | ±0 | Laggard | loss narrowed 33% | -14% | — | 13 | 2026-08-11 |
| IMRX | Immuneering Corporation Class A Common Stock | 26 | -1 | Laggard | loss narrowed 33%↓ | -100% | — | 26 | 2026-08-05 |
| OCUL | Ocular Therapeutix, Inc. | 26 | ±0 | Laggard | loss narrowed 10%↑ | 0% | <-10,000 bps | 65 | 2026-08-03 |
| TVRD | Tvardi Therapeutics, Inc. Common Stock | 26 | ±0 | Laggard | loss narrowed 31%↓ | +20% | — | 10 | 2026-08-14 |
| FATE | Fate Therapeutics, Inc. | 25 | ±0 | Laggard | loss narrowed 14%↓ | +9%↑ | — | 96 | 2026-08-13 |
| LPCN | Lipocine Inc. | 25 | ±0 | Laggard | loss narrowed 22%↑ | -69% | — | 4 | 2026-08-04 |
| LSTA | Lisata Therapeutics, Inc. Common Stock | 25 | ±0 | Laggard | loss narrowed 41% | -100% | — | 6 | 2026-08-06 |
| ABT | Abbott Laboratories | 24 | -1 | Laggard | -20% | +8% | +23 bps | 41 | 2026-07-28 |
| BCYC | Bicycle Therapeutics plc American Depositary Shares | 24 | ±0 | Laggard | loss narrowed 37% | -78% | >+10,000 bps | 21 | 2026-07-30 |
| GYRE | Gyre Therapeutics, Inc. Common Stock | 24 | ±0 | Laggard | to loss | +9% | -2304 bps | 26 | 2026-08-07 |
| TCRX | TScan Therapeutics, Inc. Common Stock | 24 | -1 | Laggard | loss narrowed 18% | -66%↓ | — | 5 | 2026-08-12 |
| AARD | Aardvark Therapeutics, Inc. Common Stock | 23 | ±0 | Laggard | loss widened 0% | — | — | 44 | 2026-08-11 |
| AKTX | Akari Therapeutics plc ADR (0.01 USD) | 23 | ±0 | Laggard | 0% | -39% | — | — | 2026-08-13 |
| AVTX | Avalo Therapeutics, Inc. Common Stock | 23 | -1 | Laggard | loss narrowed 57%↑ | -100%↓ | — | 50 | 2026-08-06 |
| IBO | Impact BioMedical, Inc. | 23 | ±0 | Laggard | loss narrowed 99% | -57% | — | 26 | 2026-08-07 |
| IDYA | IDEAYA Biosciences, Inc. Common Stock | 23 | ±0 | Laggard | loss widened 39%↓ | — | — | 63 | 2026-08-04 |
| IGC | IGC Pharma, Inc. | 23 | -1 | Laggard | loss widened 50%↓ | -19%↓ | — | 45 | 2026-08-14 |
| OGN | Organon & Co. | 23 | -1 | Laggard | -29% | -2%↑ | -259 bps | 97 | 2026-07-31 |
| TXMD | TherapeuticsMD, Inc. | 23 | ±0 | Laggard | -80% | -9% | — | 38 | 2026-08-11 |
| BHC | Bausch Health Companies Inc | 22 | ±0 | Laggard | +70% | +13%↑ | -805 bps | 65 | 2026-07-30 |
| GLAS | Glass House Brands Inc. | 22 | -1 | Laggard | loss widened 162% | -9% | -1194 bps | — | 2026-08-13 |
| TLPH | Talphera, Inc. Common Stock | 22 | ±0 | Laggard | loss narrowed 40% | — | — | 87 | 2026-08-12 |
| VTRS | Viatris Inc. Common Stock | 22 | ±0 | Laggard | to loss | +5% | +1791 bps | 71 | 2026-08-06 |
| ACRS | Aclaris Therapeutics, Inc. | 21 | ±0 | Laggard | loss widened 15% | -8% | — | 91 | 2026-08-06 |
| AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | 21 | ±0 | Laggard | loss narrowed 15% | — | — | 97 | 2026-08-06 |
| MYGN | Myriad Genetics Inc | 21 | ±0 | Laggard | loss narrowed 87% | -11% | +3788 bps | 16 | 2026-07-31 |
| NAII | Natural Alternatives International Inc. | 21 | -1 | Laggard | loss widened 95%↓ | +23% | +206 bps | 21 | 2026-05-19 |
| SCLX | Scilex Holding Company Common Stock | 21 | ±0 | Laggard | loss widened 124%↑ | -23% | <-10,000 bps | 11 | 2026-08-14 |
| SER | Serina Therapeutics, Inc. | 21 | ±0 | Laggard | loss narrowed 17%↑ | -100% | — | 93 | 2026-08-13 |
| TENX | Tenax Therapeutics, Inc. | 21 | ±0 | Laggard | loss widened 30% | — | — | 2 | 2026-07-31 |
| ANVS | Annovis Bio, Inc. | 20 | -1 | Laggard | loss widened 25% | — | — | 9 | 2026-08-14 |
| HIND | Vyome Holdings, Inc. Common Stock | 20 | ±0 | Laggard | loss narrowed 96% | -98% | — | 27 | 2026-08-12 |
| MRK | Merck & Co., Inc.Obesity & Weight-Loss Therapeutics | 20 | ±0 | Laggard | to loss | +5% | -2119 bps | 79 | 2026-08-07 |
| PBYI | PUMA BIOTECHNOLOGY INC | 20 | -1 | Laggard | +33% | +8% | -619 bps | 91 | 2026-08-06 |
| AZTR | Azitra Inc | 19 | ±0 | Laggard | loss narrowed 6%↑ | — | — | 41 | 2026-08-12 |
| GILD | Gilead Sciences IncHuman Therapeutics | 19 | ±0 | Laggard | to loss | +10% | -3609 bps | 48 | 2026-08-06 |
| IPHA | Innate Pharma S.A. ADS | 19 | -1 | Laggard | loss narrowed 10% | -78% | — | 76 | 2026-04-01 |
| NEOG | Neogen Corp | 19 | ±0 | Laggard | — | — | +4162 bps | 73 | 2026-07-30 |
| TNGX | Tango Therapeutics, Inc. | 19 | ±0 | Laggard | loss widened 6%↓ | -100% | >+10,000 bps | 86 | 2026-08-11 |
| VYGR | Voyager Therapeutics, Inc. Common Stock | 19 | ±0 | Laggard | loss narrowed 30% | -39% | -5028 bps | 16 | 2026-08-06 |
| IMNN | Imunon, Inc. Common Stock | 18 | -1 | Laggard | loss narrowed 75%↑ | 0% | — | 9 | 2026-08-11 |
| TBPH | Theravance Biopharma, Inc. | 18 | -1 | Laggard | to loss↓ | -21%↓ | +4415 bps | 77 | 2026-08-11 |
| XCUR | Exicure, Inc. Common Stock | 18 | -1 | Laggard | loss narrowed 56% | — | — | 6 | 2026-08-14 |
| AIM | AIM ImmunoTech Inc. | 17 | ±0 | Laggard | loss narrowed 88%↑ | +4% | — | 6 | 2026-08-07 |
| ARTV | Artiva Biotherapeutics, Inc. Common Stock | 17 | ±0 | Laggard | loss narrowed 28%↑ | — | — | 89 | 2026-08-06 |
| BIIB | Biogen Inc. Common StockHuman Therapeutics | 17 | -1 | Laggard | +31% | +2% | -152 bps | 66 | 2026-07-29 |
| BTMD | Biote Corp. Class A Common Stock | 17 | -1 | Laggard | to loss↓ | -9%↓ | -975 bps | 23 | 2026-08-07 |
| CMPX | Compass Therapeutics, Inc. Common Stock | 17 | ±0 | Laggard | loss narrowed 7%↓ | — | — | 7 | 2026-08-06 |
| ENVB | Enveric Biosciences, Inc. Common Stock | 17 | -1 | Laggard | loss narrowed 22%↑ | -7% | — | 21 | 2026-08-14 |
| MBIO | Mustang Bio, Inc. | 17 | ±0 | Laggard | loss narrowed 16% | — | — | 11 | 2026-08-05 |
| SLDB | Solid Biosciences Inc. Common Stock | 17 | ±0 | Laggard | loss narrowed 10% | -100% | — | 72 | 2026-08-06 |
| ELTX | Elicio Therapeutics, Inc. Common Stock | 16 | ±0 | Laggard | loss narrowed 35% | -100% | — | 3 | 2026-08-13 |
| FULC | Fulcrum Therapeutics, Inc. Common Stock | 16 | ±0 | Laggard | loss widened 21% | — | — | 10 | 2026-07-30 |
| KPTI | Karyopharm Therapeutics Inc. | 16 | -1 | Laggard | loss narrowed 46% | -12% | +2776 bps | 3 | 2026-08-13 |
| LRMR | Larimar Therapeutics, Inc. Common Stock | 16 | ±0 | Laggard | loss widened 154% | — | — | 19 | 2026-08-04 |
| MNPR | Monopar Therapeutics Inc. Common Stock | 16 | ±0 | Laggard | loss widened 77%↓ | — | — | 96 | 2026-08-12 |
| COGT | Cogent Biosciences, Inc. Common Stock | 15 | -1 | Laggard | loss narrowed 2%↑ | -100% | — | 42 | 2026-08-10 |
| CRBP | Corbus Pharmaceuticals Holdings, Inc.Obesity & Weight-Loss Therapeutics | 15 | ±0 | Laggard | loss widened 26% | -100% | — | 25 | 2026-08-06 |
| CTNM | Contineum Therapeutics, Inc. Class A Common Stock | 15 | ±0 | Laggard | loss narrowed 0% | -100% | — | 46 | 2026-07-30 |
| HRTX | Heron Therapeutics, Inc. | 15 | ±0 | Laggard | loss widened 50% | +1% | -801 bps | 6 | 2026-08-10 |
| TRAW | Traws Pharma, Inc. Common Stock | 15 | -1 | Laggard | loss widened 45% | -100% | — | 5 | 2026-08-14 |
| WHWK | Whitehawk Therapeutics, Inc. Common Stock | 15 | ±0 | Laggard | loss narrowed 74% | — | — | 52 | 2026-08-06 |
| IMNM | Immunome, Inc. | 14 | ±0 | Laggard | loss widened 30%↓ | -100% | — | 71 | 2026-08-11 |
| INBX | Inhibrx Biosciences, Inc. Common Stock | 14 | ±0 | Laggard | loss widened 26%↓ | -100% | — | 91 | 2026-08-13 |
| LFVN | Lifevantage Corporation Common Stock (Delaware) | 14 | +6 | Laggard | -37%↑ | -23%↑ | -200 bps | 75 | 2026-08-27 |
| MDWD | MediWound Ltd. | 14 | ±0 | Laggard | loss widened 81% | +13% | <-10,000 bps | 25 | 2026-03-05 |
| PFE | Pfizer Inc.Obesity & Weight-Loss TherapeuticsHuman Therapeutics | 14 | -1 | Laggard | to loss | +3% | -990 bps | 51 | 2026-08-04 |
| ZBIO | Zenas BioPharma, Inc. Common Stock | 14 | ±0 | Laggard | loss widened 42%↑ | — | — | 77 | 2026-08-13 |
| ZNTL | Zentalis Pharmaceuticals, Inc. Common Stock | 14 | ±0 | Laggard | loss widened 59%↓ | -100% | — | 76 | 2026-08-06 |
| MGX | Metagenomi Therapeutics, Inc. Common Stock | 13 | ±0 | Laggard | loss widened 35% | -70%↓ | — | 19 | 2026-08-10 |
| NRIX | Nurix Therapeutics, Inc. Common stock | 13 | ±0 | Laggard | loss widened 56%↓ | -79%↓ | <-10,000 bps | 93 | 2026-07-09 |
| NTHI | NeOnc Technologies Holdings, Inc. Common Stock | 13 | ±0 | Laggard | loss widened 93% | — | — | 7 | 2026-08-10 |
| RMTI | Rockwell Medical, Inc. (DE) Common Stock | 13 | ±0 | Laggard | loss widened 570%↓ | +11%↑ | -505 bps | 35 | 2026-08-13 |
| SMMT | Summit Therapeutics Inc. Common Stock | 13 | -1 | Laggard | loss narrowed 63%↑ | — | — | 58 | 2026-07-23 |
| TSHA | Taysha Gene Therapies, Inc. Common Stock | 13 | ±0 | Laggard | loss widened 44% | -100% | — | 68 | 2026-08-11 |
| USNA | USANA Health Sciences Inc | 13 | ±0 | Laggard | to loss | -5%↓ | -637 bps | 30 | 2026-08-13 |
| ABCL | AbCellera Biologics Inc. Common SharesGenomics & Precision-Medicine Tools | 12 | -1 | Laggard | loss widened 50%↓ | -76%↓ | >+10,000 bps | 98 | 2026-08-05 |
| BMRA | BIOMERICA INC | 12 | +9 | Laggard | loss narrowed 79%↑ | +17%↑ | — | 64 | 2026-08-31 |
| CADL | Candel Therapeutics, Inc. Common Stock | 12 | ±0 | Laggard | loss widened 478%↓ | 0% | — | 97 | 2026-08-13 |
| CAPR | Capricor Therapeutics IncHuman Therapeutics | 12 | ±0 | Laggard | loss widened 23% | -8% | — | 4 | 2026-08-14 |
| LEGN | Legend Biotech Corporation American Depositary SharesHuman Therapeutics | 12 | -1 | Laggard | to loss | — | — | 42 | 2026-03-10 |
| RVMD | Revolution Medicines, Inc. Common StockHuman Therapeutics | 12 | ±0 | Laggard | loss widened 134%↓ | — | — | 96 | 2026-08-05 |
| BDTX | Black Diamond Therapeutics, Inc. Common Stock | 11 | ±0 | Laggard | loss narrowed 11% | — | — | 33 | 2026-08-05 |
| ABVX | Abivax SA American Depositary Shares | 10 | ±0 | Laggard | loss widened 81% | -90% | — | 54 | 2026-03-23 |
| AKBA | Akebia Therapeutics, Inc. | 10 | ±0 | Laggard | to loss | -21%↓ | -729 bps | 17 | 2026-08-05 |
| BNTX | BioNTech SE American Depositary Share | 10 | ±0 | Laggard | loss widened 70% | +4% | -118 bps | 59 | 2026-08-04 |
| CLDX | Celldex Therapeutics, Inc | 10 | -1 | Laggard | loss widened 11%↑ | -97% | — | 76 | 2026-08-06 |
| DNA | Ginkgo Bioworks Holdings, Inc. | 10 | ±0 | Laggard | loss narrowed 32% | -59% | <-10,000 bps | 48 | 2026-08-06 |
| MOLN | Molecular Partners AG American Depositary Shares | 10 | ±0 | Laggard | loss widened 4% | -100% | — | 35 | 2026-03-12 |
| PRAX | Praxis Precision Medicines, Inc. Common StockHuman Therapeutics | 10 | ±0 | Laggard | loss narrowed 13%↑ | -100% | — | 68 | 2026-08-06 |
| TEVA | Teva Pharmaceutical Industries Limited American Depositary Shares | 10 | ±0 | Laggard | to loss↓ | -1%↓ | — | 73 | 2026-07-29 |
| TIL | Instil Bio, Inc. Common Stock | 10 | ±0 | Laggard | loss narrowed 81% | — | — | 27 | 2026-08-13 |
| XENE | Xenon Pharmaceuticals IncHuman Therapeutics | 10 | ±0 | Laggard | loss widened 4%↑ | — | — | 48 | 2026-08-06 |
| XNCR | Xencor, Inc. | 10 | ±0 | Laggard | loss narrowed 29% | +17% | <-10,000 bps | 96 | 2026-08-05 |
| CRVO | CervoMed Inc. Common Stock | 9 | ±0 | Laggard | loss narrowed 9% | -100% | — | 12 | 2026-08-07 |
| DNTH | Dianthus Therapeutics, Inc. Common Stock | 9 | -1 | Laggard | loss widened 2%↑ | -79%↑ | — | 75 | 2026-08-04 |
| SVRA | Savara Inc. | 9 | ±0 | Laggard | loss widened 14% | -100% | — | 44 | 2026-08-11 |
| VBIO | Valion Bio, Inc. Common Stock | 9 | ±0 | Laggard | loss narrowed 1%↓ | +16%↑ | — | — | 2026-08-14 |
| LITS | Lite Strategy, Inc. Common Stock | 8 | ±0 | Laggard | loss widened 69% | — | — | 37 | 2026-05-13 |
| ORKA | Oruka Therapeutics, Inc. Common StockHuman Therapeutics | 8 | ±0 | Laggard | loss widened 156%↑ | — | — | 98 | 2026-08-10 |
| QDEL | QuidelOrtho Corporation Common Stock | 8 | ±0 | Laggard | loss narrowed 64% | +3% | -2232 bps | 17 | 2026-08-07 |
| SILO | Silo Pharma, Inc. Common Stock | 8 | ±0 | Laggard | loss widened 300%↓ | -100% | — | 7 | 2026-08-13 |
| TRDA | Entrada Therapeutics, Inc. Common Stock | 8 | ±0 | Laggard | loss narrowed 3%↑ | -54%↑ | — | 9 | 2026-08-05 |
| VERU | Veru Inc. | 8 | -1 | Laggard | loss narrowed 40%↑ | -100% | — | 47 | 2026-08-10 |
| VKTX | Viking Therapeutics, IncObesity & Weight-Loss TherapeuticsHuman Therapeutics | 8 | ±0 | Laggard | loss widened 90%↑ | — | — | 36 | 2026-07-29 |
| CTMX | CytomX Therapeutics, Inc. | 7 | ±0 | Laggard | to loss↑ | -92% | <-10,000 bps | 18 | 2026-08-06 |
| KROS | Keros Therapeutics, Inc. Common Stock | 7 | ±0 | Laggard | loss widened 91% | -100%↓ | <-10,000 bps | 47 | 2026-08-03 |
| NVAX | Novavax Inc | 7 | ±0 | Laggard | to loss↓ | -76% | -8914 bps | 32 | 2026-08-06 |
| VALN | Valneva SE American Depositary Shares | 7 | -1 | Laggard | loss widened 16% | -10% | -5484 bps | 13 | 2026-03-17 |
| VNDA | Vanda Pharmaceuticals Inc. | 7 | -1 | Laggard | loss widened 126% | -4%↓ | -3652 bps | 11 | 2026-08-06 |
| ATRA | Atara Biotherapeutics, Inc | 6 | ±0 | Laggard | to loss↓ | -96% | — | 92 | 2026-08-12 |
| CELZ | Creative Medical Technology Holdings, Inc. Common Stock | 6 | ±0 | Laggard | loss narrowed 15% | — | — | 10 | 2026-08-07 |
| CTXR | Citius Pharmaceuticals Inc. Common | 6 | -1 | Laggard | loss narrowed 57% | — | — | 15 | 2026-08-14 |
| NAMS | NewAmsterdam Pharma Company N.V. Ordinary Shares | 6 | -1 | Laggard | loss widened 247%↓ | -81% | — | 18 | 2026-08-05 |
| NKTR | Nektar Therapeutics | 6 | -1 | Laggard | loss narrowed 58%↑ | -9% | <-10,000 bps | 44 | 2026-08-14 |
| PMCB | PharmaCyte Biotech, Inc. Common Stock | 6 | ±0 | Laggard | to loss | — | — | 16 | 2026-07-29 |
| QCLS | Q/C Technologies, Inc. Common Stock | 6 | ±0 | Laggard | loss widened 339% | -100% | — | 8 | 2026-08-12 |
| SDEV | Stablecoin Development Corporation | 6 | ±0 | Laggard | loss widened 300% | — | — | — | 2026-07-30 |
| YARW | Yarrow Bioscience, Inc. Common Stock | 6 | -1 | Laggard | loss widened 999% | +41%↑ | — | — | 2026-08-13 |
| ALMS | Alumis Inc. Common Stock | 5 | ±0 | Laggard | to loss | -38%↑ | — | 7 | 2026-08-13 |
| AYTU | AYTU BioPharma, Inc. Common Stock | 5 | ±0 | Laggard | to loss↓ | -33% | -2122 bps | 25 | 2026-05-13 |
| IRD | Opus Genetics, Inc. Common Stock | 5 | ±0 | Laggard | loss widened 17% | -74%↓ | — | 76 | 2026-08-06 |
| NERV | Minerva Neurosciences, Inc | 5 | -1 | Laggard | loss narrowed 67%↑ | — | — | 12 | 2026-08-07 |
| NGNE | Neurogene, Inc. Common Stock | 5 | -1 | Laggard | loss widened 46%↓ | — | — | 92 | 2026-08-11 |
| OGEN | Oragenics Inc. | 5 | -1 | Laggard | loss narrowed 82% | — | — | 12 | 2026-08-13 |
| PCSA | Processa Pharmaceuticals, Inc. Common | 5 | ±0 | Laggard | loss widened 376% | — | — | 15 | 2026-08-14 |
| PRGO | PERRIGO COMPANY PLC | 5 | ±0 | Laggard | to profit | -3% | -4435 bps | 87 | 2026-08-05 |
| SIGA | SIGA Technologies Inc. | 5 | -1 | Laggard | -65% | -49% | -7701 bps | 12 | 2026-08-06 |
| TRLV | Trulieve Cannabis Corp. | 5 | ±0 | Laggard | loss widened 999% | -10%↓ | -3176 bps | — | 2026-08-07 |
| UNCY | Unicycive Therapeutics, Inc. Common Stock | 5 | ±0 | Laggard | loss widened 198% | -29% | — | 22 | 2026-08-12 |
| VRAX | Virax Biolabs Group Limited Ordinary Shares | 5 | ±0 | Laggard | loss narrowed 52% | -96% | — | 12 | 2026-07-06 |
| XBIT | XBiotech Inc | 5 | ±0 | Laggard | loss widened 267% | -100% | — | 39 | 2026-08-13 |
| BON | Bon Natural Life Limited Class A Ordinary Shares | 4 | ±0 | Laggard | to loss | -22% | -1655 bps | 23 | 2026-01-23 |
| EDSA | Edesa Biotech, Inc. Common Shares | 4 | ±0 | Laggard | loss widened 140%↓ | -100% | — | 19 | 2026-08-13 |
| GLUE | Monte Rosa Therapeutics, Inc. Common Stock | 4 | ±0 | Laggard | loss widened 187% | -61%↑ | <-10,000 bps | 29 | 2026-08-06 |
| MTNB | Matinas BioPharma Holdings, Inc. | 4 | ±0 | Laggard | loss narrowed 80% | — | — | 6 | 2026-08-13 |
| PVLA | Palvella Therapeutics, Inc. Common Stock | 4 | ±0 | Laggard | loss widened 77%↓ | -100% | — | 60 | 2026-08-04 |
| SPRO | Spero Therapeutics, Inc. Common Stock | 4 | ±0 | Laggard | loss widened 433%↓ | — | — | 8 | 2026-08-12 |
| ARCT | Arcturus Therapeutics Holdings Inc. Common Stock | 3 | ±0 | Laggard | loss widened 147%↓ | -90% | <-10,000 bps | 95 | 2026-08-06 |
| CPIX | Cumberland Pharmaceuticals Inc | 3 | ±0 | Laggard | loss widened 480%↓ | -19% | -1701 bps | 97 | 2026-08-07 |
| CRIS | Curis Inc | 3 | ±0 | Laggard | loss widened 491%↓ | -100% | — | 2 | 2026-08-14 |
| ORGO | Organogenesis Holdings Inc. Class A Common Stock | 3 | ±0 | Laggard | loss widened 670%↓ | -57% | -252 bps | 12 | 2026-08-06 |
| SXTC | China SXT Pharmaceuticals, Inc. Class A Ordinary Shares | 3 | ±0 | Laggard | loss widened 293% | -35% | — | — | 2026-07-01 |
| TCRT | Alaunos Therapeutics, Inc. Common Stock | 3 | ±0 | Laggard | loss narrowed 35% | — | — | 9 | 2026-08-14 |
| BOLT | Bolt Biotherapeutics, Inc. Common Stock | 2 | ±0 | Laggard | loss widened 2%↑ | -100%↓ | — | 37 | 2026-08-11 |
| CATX | Perspective Therapeutics, Inc. | 2 | ±0 | Laggard | loss narrowed 24% | -72%↑ | — | 11 | 2026-08-10 |
| CELU | Celularity Inc. Class A Common Stock | 2 | ±0 | Laggard | loss widened 47% | -77% | <-10,000 bps | 65 | 2026-04-30 |
| DCOY | Decoy Therapeutics Inc. Common Stock | 2 | ±0 | Laggard | loss widened 891% | — | — | 6 | 2026-08-12 |
| KALA | KALA BIO, Inc. Common Stock | 2 | -40 | Laggard | loss widened 999%↓ | -100%↓ | — | 1 | 2026-08-19 |
| MBRX | Moleculin Biotech, Inc. | 2 | ±0 | Laggard | loss widened 22%↑ | — | — | 8 | 2026-08-13 |
| NXTC | NextCure, Inc. Common Stock | 2 | ±0 | Laggard | loss narrowed 75% | -100% | — | 11 | 2026-08-06 |
| STRO | Sutro Biopharma, Inc. | 2 | ±0 | Laggard | loss widened 999% | -85% | <-10,000 bps | 20 | 2026-08-12 |
| APVO | Aptevo Therapeutics Inc | 1 | ±0 | Laggard | loss narrowed 37% | -100% | — | 8 | 2026-08-14 |
| CANF | Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares | 1 | ±0 | Laggard | to loss | -40% | — | 11 | 2026-03-26 |
| ELAB | PMGC Holdings Inc. Common Stock | 1 | ±0 | Laggard | loss widened 30%↑ | — | — | 2 | 2026-08-14 |
| GNPX | Genprex, Inc. Common Stock | 1 | ±0 | Laggard | loss widened 999% | — | — | 2 | 2026-08-14 |
| GRI | GRI Bio, Inc. Common Stock | 1 | ±0 | Laggard | loss narrowed 31% | — | — | 16 | 2026-08-14 |
| HELP | Cybin Inc. Common Stock | 1 | ±0 | Laggard | loss widened 999% | -100% | — | 98 | 2026-06-29 |
| IMA | ImageneBio, Inc. Common Stock | 1 | ±0 | Laggard | loss widened 950% | — | — | 29 | 2026-08-05 |
| KYNB | Kyntra Bio, Inc. Common Stock | 1 | ±0 | Laggard | to profit | -209%↓ | — | 65 | 2026-08-13 |
| LYEL | Lyell Immunopharma, Inc. Common Stock | 1 | -1 | Laggard | loss narrowed 34%↑ | -50% | — | 10 | 2026-08-06 |
| NXTS | Nexentis Technologies Inc. Common Stock | 1 | ±0 | Laggard | loss widened 999% | -78% | — | 5 | 2026-08-13 |
| ONCO | Onconetix, Inc. Common Stock | 1 | ±0 | Laggard | loss narrowed 73% | -84%↓ | — | 1 | 2026-08-13 |
| PTHS | Pelthos Therapeutics Inc. | 1 | ±0 | Laggard | loss widened 23% | — | — | 34 | 2026-08-13 |
| PTN | Palatin Technologies, Inc. Common Stock | 1 | ±0 | Laggard | loss widened 106% | -56% | — | 11 | 2026-05-13 |
| RNAC | Cartesian Therapeutics, Inc. Common Stock | 1 | ±0 | Laggard | -8%↑ | — | — | 52 | 2026-08-06 |
| SNYR | Synergy CHC Corp. Common Stock | 1 | ±0 | Laggard | to loss | -33% | -5730 bps | 2 | 2026-05-14 |
| SPRB | Spruce Biosciences, Inc. Common Stock | 1 | ±0 | Laggard | loss widened 91%↑ | -100% | — | 30 | 2026-08-12 |
| ZYBT | Zhengye Biotechnology Holding Limited Class A Ordinary Shares | 1 | ±0 | Laggard | to loss | -35% | <-10,000 bps | — | 2026-04-28 |
| ZYME | Zymeworks Inc.Human Therapeutics | 1 | ±0 | Laggard | to loss↓ | -91%↑ | <-10,000 bps | 57 | 2026-08-06 |
Every US common stock and ADR in the universe is ranked on fundamental growth from the numbers companies actually filed with the SEC — no analyst estimates, no forward projections. TickerStance reads EDGAR XBRL company facts directly.
To qualify, a company must have at least six quarters of EPS and revenue history available and the most-recent filing must be no older than 200 days. That gate keeps the rankings grounded in current operating conditions rather than stale data.
Two growth factors are computed: recent year-over-year growth (latest quarter vs the same quarter last year) blended with a three-year trend score. Both factors are percentile-ranked universe-wide so a rank of 90 means the company grows faster than 90% of its peers, regardless of absolute size. The two factor percentiles are then combined into a single 1-99 fundamentals rank.
Operating margin is tracked as context — a company whose margins are expanding while growing revenue is a stronger story than one shrinking margins to buy growth — but margin level is not a direct rank input. Industries, sectors, and themes inherit their rank from the median of their members, so a strong cluster is one where most constituent companies score well, not just a few outliers.
The RS overlap metric shows what share of a cluster's eligible companies sit in the top relative-strength quintile (6M RS rank ≥ 80). When a fundamentally strong group also carries broad price leadership, it has both the earnings story and the institutional sponsorship — the combination that historically precedes sustained outperformance.
Every US common stock and ADR with sufficient SEC filing history gets a 1-99 fundamentals rank: EPS and revenue growth factors are computed from filed XBRL data, percentile-ranked across the universe, and blended. Ranks of 90+ are Leaders, 70-89 Strong, 30-69 Average, below 30 Laggards. Industries, sectors, and themes are then ranked by their members' median rank.
SEC EDGAR XBRL company facts — the numbers companies actually filed. No analyst estimates, no forward guidance, no third-party data vendor.
Sign-aware: a narrowed loss counts as improvement, a widened loss as deterioration, a swing to profit as a turnaround. Conventional percent math misreads losses (a loss shrinking from -$0.12 to -$0.07 is improvement, not "down 42%"), so the table says "loss narrowed 42%" instead of printing a misleading percentage.
The change in a group's median fundamentals rank versus 15 and 30 trading days ago — the classic "improving group" read. Positive means the group is gaining rank. Dashes mean the history window isn't available yet.
Once per US trading day after the close. The as-of date in the header is the snapshot date.